Cresco Labs Inc. (CRLBF) Liabilities and Shareholders Equity (2019 - 2026)

Cresco Labs (CRLBF) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 6.27% year-over-year to $1.3 billion; the trailing twelve-month figure through Jun 2026 stood at $4.9 billion (down 9.36% YoY), and the FY2025 full-year result was $1.2 billion, down 11.66% from the prior year.
• Liabilities and Shareholders Equity climbed to $1.3 billion in Q2 2026 per CRLBF's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.8 billion in Q1 2022 and bottomed at $1.2 billion in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity grew 26.85% in 2022, then dropped 20.33% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.6 billion in 2022, then slipped by 14.22% to $1.4 billion in 2023, then slipped by 0.23% to $1.4 billion in 2024, then dropped by 11.66% to $1.2 billion in 2025, then climbed by 5.51% to $1.3 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.3 billion, $1.2 billion, and $1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.